SURMOUNT-1 trial finds tilsiparatide/tilpotide supports long-term weight control

A new study likely to be released in May 2025 shows that about two-thirds of SURMOUNT-1 trial participants had regained 5% or less of their so-called nadir (or nadir) body weight three years after starting treatment with Tirzepatide. Obesity management is a long-term process during which weight fluctuations are expected. For some patients, a previous nadir (or lowest) weight may become a point of concern (and disappointing when it cannot be reached again). However, there is currently no clear literature demonstrating that minimum body weight is clinically relevant. This post hoc analysis of the SURMOUNT-1 study after 3 years was designed to assess recovery from nadir weight after 3 years (36 months/176 weeks) of tilsiparatide treatment.

The originalSURMOUNT-1 trial, published in 2022, found substantial and sustained weight loss over 72 weeks in obese participants treated with 5 mg, 10 mg or 15 mg of tilsiparatide once weekly.

This analysis included690 tilsiparatide-adherent participants (65% female, 35% male) with a mean age of 49 years, a mean weight of 107 kg, and a mean BMI of 38.6 kg/m2 who were selected from the original SURMOUNT-1 cohort because they remained adherent over 3 years. are on treatment (receiving 75% or more of the planned dose) and have obesity (BMI of at least 30 kg/mm2), overweight (BMI of at least 27 kg/cm2), and prediabetes, and are participants in the SURMOUNT-1 study who have lost at least 5% of their baseline body weight by the time they reach nadir weight (the lowest weight achieved during treatment).

Weight recovery from nadir to week Weight recovery from nadir to week 176 was defined as the difference between the percent weight loss from baseline to nadir and the percent weight loss from baseline to week 176. Weight recovery analysis was calculated as the mean across groups and categorized as less than 5%, 5% to 10%, and 10% or more weight recovery.

The analysis showed that the average time to weight nadir was 22 months (96 weeks). The average weight loss percentage at lowest weight was 23.1%. The average percent weight regain from lowest weight to week 176 was 3.7%, which means the average percent weight loss among the 690 participants over the three years was 19.4% (23.1% minus 3.7%).

At At 176 weeks, 73%, 19%, and 8% of subjects (227 subjects) had regained less than 5%, 5% to 10%, and 10% or more, respectively, from their nadir body weight. Similarly, from nadir to week 176, 65%, 26%, and 9% of participants (N = 239) who received tilsiparatide 10 mg regained less than 5%, 5% to 10%, and 10% or more, respectively. Among participants who received tilsiparatide 15 mg (N=224), 73%, 20%, and 7% of participants achieved weight regain of less than 5%, 5% to 10%, and 10% or more, respectively, from nadir to week 176.

Reference materials:https://www.news-medical.net/news/20250411/SURMOUNT-1-trial-finds-tirzepatide-supports-long-term-weight-control.aspx